Literature DB >> 1832440

Seroprevalence of hepatitis B virus infection in children in Taipei, 1989: five years after a mass hepatitis B vaccination program.

Y J Tsen1, M H Chang, H Y Hsu, C Y Lee, J L Sung, D S Chen.   

Abstract

A nationwide hepatitis B vaccination program was launched in Taiwan in 1984. To study the impact of this ongoing program on hepatitis B virus (HBV) infection, a follow-up seroepidemiologic study was carried out in 1989 in a Taipei district where pre-vaccination seroepidemiology had been studied. HBV markers were studied in 1134 apparently healthy children (619 boys and 515 girls) under 13 years of age between March and July 1989. The prevalence of hepatitis B surface antigen (HBsAg) in children under 5 years of age decreased from 9.3% in 1984 to approximately 2% in 1989. A significant decrease in HBsAg prevalence and hepatitis B core antibody in 5- to 8-year-old children who were not immunized against HBV showed that horizontal infection among the older children had also decreased. Thus, this program not only protected vaccinated subjects; the reduction in numbers of highly infectious young HBV carriers also contributed to a lower prevalence of hepatitis B infection and carrier rates in some older children. This study demonstrates that hepatitis B vaccination is effective in protecting the majority of children in hyperendemic areas from HBV infection and from becoming chronic carriers.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1832440     DOI: 10.1002/jmv.1890340205

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  18 in total

1.  Persistence of hepatitis B vaccine immune protection and response to hepatitis B booster immunization.

Authors:  Hui Li; Rong-Cheng Li; Su-Su Liao; Jin-Ye Yang; Xian-Jia Zeng; Shu-Sheng Wang
Journal:  World J Gastroenterol       Date:  1998-12       Impact factor: 5.742

Review 2.  Chronic viral hepatitis.

Authors:  M H Chang
Journal:  Indian J Pediatr       Date:  1995 Nov-Dec       Impact factor: 1.967

Review 3.  Hepatitis B vaccine: a pharmacoeconomic evaluation of its use in the prevention of hepatitis B virus infection.

Authors:  S M Holliday; D Faulds
Journal:  Pharmacoeconomics       Date:  1994-02       Impact factor: 4.981

4.  Hepatitis B vaccination in preterm infants.

Authors:  F Y Huang; P I Lee; C Y Lee; L M Huang; L Y Chang; S C Liu
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1997-09       Impact factor: 5.747

5.  Impact of the Expanded Program of Immunization against hepatitis B infection in school children in Malaysia.

Authors:  K P Ng; T L Saw; A Baki; K Rozainah; K W Pang; M Ramanathan
Journal:  Med Microbiol Immunol       Date:  2004-10-19       Impact factor: 3.402

Review 6.  Viral hepatitis.

Authors:  G V Gregorio; G Mieli-Vergani; A P Mowat
Journal:  Arch Dis Child       Date:  1994-04       Impact factor: 3.791

7.  Long-term follow-up of Hepatitis B Surface antibody levels in subjects receiving universal Hepatitis B vaccination in infancy in an area of hyperendemicity: correlation between radioimmunoassay and enzyme immunoassay.

Authors:  Ching-Wen Wang; Li-Chieh Wang; Mei-Hwei Chang; Yen-Hsuan Ni; Huey-Ling Chen; Hong-Yuan Hsu; Ding-Shin Chen
Journal:  Clin Diagn Lab Immunol       Date:  2005-12

Review 8.  Epidemiology of hepatitis B infection in the Western Pacific and South East Asia.

Authors:  I D Gust
Journal:  Gut       Date:  1996       Impact factor: 23.059

Review 9.  Immunisation against hepatitis B in Taiwan.

Authors:  I D Gust
Journal:  Gut       Date:  1996       Impact factor: 23.059

10.  Hepatitis B Infection in Canada: Epidemiology and implications for control.

Authors:  G Delage; A O Carter
Journal:  Can Fam Physician       Date:  1992-11       Impact factor: 3.275

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.